Antimicrobial resistance of Helicobacter pylori in an eastern German region. Issue 1 (17th October 2020)

• Record Type: Journal Article
• Authors: Hofreuter, Dirk; Behrendt, Johannes; Franz, Annett; Meyer, Jens; Jansen, Anna; Bluemel, Benjamin; Eisele, Bianca; Koken, Miriam; Glocker, Erik‐Oliver
• Is Part Of: Helicobacter. Volume 26:Issue 1(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-10-17
• Subjects: antimicrobial susceptibility -- genotypic resistance -- surveillance; Helicobacter -- Periodicals; Helicobacter infections -- Periodicals; Stomach -- Diseases -- Periodicals; 616.3301405
• DOI: 10.1111/hel.12765
• Languages: English
• ISSNs: 1083-4389

Abstract

Abstract: Background: Antimicrobial therapy is recommended to eradicate Helicobacter (H.) pylori in infected individuals. As first‐line treatments are empiric, knowledge of antimicrobial resistance is key to successful eradication. Aims: We investigated primary resistance in an eastern German region to derive recommendations for eradication treatment. Methods: We used molecular genetic methods to examine Helicobacter rapid urease test (RUT) positive gastric specimens of 533 patients from Berlin and the federal state of Brandenburg with allegedly no prior eradication treatment. Tissue samples were removed from RUT and screened by real‐time PCR for mutations conferring resistance to clarithromycin. In addition, 182 samples out of 533 were tested for resistance to levofloxacin and tetracycline. Results: Primary resistances were 10.9% (58 out of 533) to clarithromycin; 13.7% (25/182) to levofloxacin; and 2.2% to tetracycline (4/182). Combined resistance to clarithromycin/levofloxacin was low (2.2%, 4/182). Female sex was significantly associated with clarithromycin resistance. Conclusion: Clarithromycin may be a suitable first‐line antibiotic for about 90% of outpatients. A simple molecular test may help physicians avoid prescription of an ineffective first‐line regimen.